WO2006095457A1

WO2006095457A1 - Therapeutic agent for malignant tumor and food or beverage containing the same

Info

Publication number: WO2006095457A1
Application number: PCT/JP2005/012747
Authority: WO
Inventors: Michio Tani
Original assignee: Michio Tani
Priority date: 2005-03-04
Filing date: 2005-07-11
Publication date: 2006-09-14
Also published as: JP2006273835A

Abstract

A therapeutic agent for malignant tumor that due to the use of food material whose safety has been proved, is entirely safe and free from side effects even if regularly administered over a prolonged period of time; and a food or beverage containing the same. There is provided a therapeutic agent for malignant tumor, comprising as an active ingredient a mixture obtained by mixing together shiitake mushroom, Grifola frondosa, lemon balm, mint and stevia.

Description

Specification

Malignant tumor therapeutic agent and food and drink containing the same

Technical field

[0001] The present invention relates to a therapeutic agent for malignant tumors (cancer, leukemia, etc.) and a food or drink containing the same. In particular, the present invention relates to a malignant tumor therapeutic agent comprising a mixture obtained by mixing shiitake mushrooms, maitake mushrooms, lemon balm, mint and stevia as active ingredients, and a food and drink containing the same.

Background art

[0002] Cancer and AIDS are intractable diseases feared all over the world. Among them, cancer accounts for about 30% of the mortality rate in Japan, and it is difficult to treat even with the three major medical treatments (surgery, radiation therapy, and anticancer drugs). Currently, for advanced cancer, it is impossible to achieve a therapeutic effect to a state that is conservatively healed or nearly cured without severe side effects, with few exceptions that are considered to be natural healing cases. ing. On the other hand, even if a cancer therapeutic agent that develops a certain curative effect in vitro or in animal experiments has been developed, it may be difficult to cure the cancer without side effects if it is used in the human body. Reality. Therefore, it is highly desired to develop a therapeutic agent for malignant tumors (cancer, leukemia, etc.) that can achieve a sufficient therapeutic effect or be cured at a meaningful fixed ratio without any side effects in actual clinical practice. This is because in the world where many human lives are deprived of cancer disease all over the world, it is the most important and final goal of medicine to protect and heal the human body.

[0003] Under such circumstances, the development of drugs with fewer side effects that are different from surgery, radiotherapy and chemotherapeutic agents has been promoted, but satisfactory results have been obtained, This is the current situation.

[0004] For example, as a conventional cancer therapeutic agent that is safe and has no side effects, at least one koji selected from Bunashimeji, Shitake, Maitake, Hatakeshimeji, and Enokitake is extracted with water, a hydrophilic solvent, or a mixed solvent thereof. An anticancer drug containing a physiologically active substance as an active ingredient can enhance the anticancer effect of a chemotherapeutic agent while having high safety, It is known that daily ingestion can prevent cancer (see, for example, Patent Document 1). However, this anticancer drug is only for preventing cancer and enhancing the anticancer effect of the chemotherapeutic agent, and there is no description of the anticancer effect in this drug itself.

[0005] In addition, a solution obtained by treating moss such as Ganoderma and Agaritas, Azabushitake, Enokidake, Shiitake, Maiko, Shimeji, Kiso, etc. with a strong alkali to be deacetylated and treated with a strong acid to form a deoxygenated bridge. Separated and mixed to neutralize the solution, added calcium chloride to the deacetylated solution, and precipitated calcium j8-glucan, and concentrated the solution to recover the polysaccharide. To make rice powder, soybeans, okara powder, and rice cake powder, and then dry powder to make ascorbic acid and citrate mixed with ascorbic acid calcium taenate j8-glucan powder. Also known as anti-diabetic and anti-hepatic agents are anti-diabetics characterized by mixing with stevia, rahan, chitin chitosan and amino acids, ganoderma spore, persimmon, green tea powder, non-chlorella, persimmon-phosphorus, pyrethroid. (See, for example, Patent Document 2). However, this anticancer agent is obtained by treating shiitake mushrooms or maiko with a strong alkali or the like, and is different from the malignant tumor therapeutic agent of the present invention.

[0006] Further, anticancer properties of geranyl phosphate synthase derived from peppermint, which is a kind of mint that is a constituent of the present invention, are known (see, for example, Patent Document 3).

[0007] However, in this document, peppermint-derived gera-lunaric acid synthase protein and monoterpene synthase protein are introduced into cancerous cells and are different from the malignant tumor therapeutic agent of the present invention.

[0008] Patent Document 1: Japanese Unexamined Patent Publication No. 2003-231644

Patent Document 2: JP 2004-10605 A

Patent Document 3: Japanese Translation of Special Publication 2001-520004

Disclosure of the invention

Problems to be solved by the invention

[0009] In view of the above circumstances, the present invention is a malignant tumor therapeutic agent that has high safety even if it is regularly used for a long time without serious side effects as seen in drugs because it is made from food materials. The purpose of this is to provide food and drinks containing it.

Means for solving the problem [0010] The object is achieved by a therapeutic agent for malignant tumors comprising as an active ingredient a mixture obtained by mixing shiitake mushroom, maitake, lemon balm, mint and stevia.

[0011] Furthermore, the object is achieved by a food or drink containing the malignant tumor therapeutic agent.

The invention's effect

[0012] The therapeutic agent for malignant tumor of the present invention and food and drink containing the same show remarkable effects for malignant tumor treatment by continuous use. However, since it is made from food materials, it is highly safe without the serious side effects seen in radiation therapy and acupuncture. In addition, the food and drink of the present invention can continuously treat malignant tumors in daily life.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, embodiments of the present invention will be described in detail.

[0014] It is known that the human body usually has at least 500 to 1000 or more cancer cells, even if it is a completely healthy person. However, the reason why it does not develop as a carcinoma is the ability of the immune function that is originally provided to quickly find cancer cells as abnormal cells and extinguish them. There are two abnormalities in cancer development: the ability to think of complex factors, namely, a decrease in immune function due to some cause (severe stress, adverse effects of diet and environment), or abnormally high number of cancer cells. It is based on. In order to repair both abnormalities in Eastern medicine, 1) Improving immune function quality 2) Enhancing immune function 3) Coordinating immune function and improving its environment It is necessary to do this. That is, the therapeutic agent for malignant tumor prepared as in the present invention is effective for enhancing the repair of these immune functions. (In addition, it has been empirically known that, in order to enhance the therapeutic effect, it is more effective to refrain from alcohol and cigarettes and vegetarian.)

[0015] The therapeutic agent for malignant tumor of the present invention comprises a mixture obtained by mixing shiitake mushroom, maitake, lemon balm, mint and stevia as an active ingredient.

[0016] In the malignant tumor therapeutic agent of the present invention, the weight ratio of shiitake mushroom, maitake, lemon balm, mint and stevia is 2 to 5: 2 to 5: 1 to 4: 0. A treatment effect of 0: 5 to 2 is preferred, and a treatment effect of 3: 3: 2: 1: 1 is particularly preferred. [0017] Furthermore, shiitake mushroom, maitake, lemon balm, mint, stevia, shimeji mushroom, celery seed and chiaichi may further contain at least one selected from the group consisting of shimeji mushroom, celery seed and chia building strength. It is preferable that the weight ratio of the building is 2-5: 2-5: 1-4: 0.5-2: 0.5-2: 2-5: 1-4: 1-4 in each dry state An effect is obtained, and 3: 3: 2: 1: 1: 1: 3: 2: 2 is particularly preferred, and a therapeutic effect is obtained.

[0018] When taking the malignant tumor therapeutic agent of the present invention, a mixture of finely chopped mixture may be taken as it is, but preferably an extract extracted with hot water is taken. In addition, it is preferable that the mixture is in a dry powder state and a dry powder that has been processed into a good shape or a hot water extracted extract is taken.

[0019] When hot water extraction is performed, the above mixture or a dried product thereof may be subjected to hot water extraction as it is. The practical surface force may be further crushed and pulverized. The weight ratio between the hot water used as the extraction solvent and the dried product is not particularly limited, but is 10 to 50 times the amount of hot water compared to the dried product, particularly 20 to 40 weights in terms of extraction operation and efficiency. Double hot water is preferred. The extraction temperature is efficient at high temperature, and 70-95 ° C is particularly good. The extraction time should be 30 minutes or more and 60 minutes or less under normal pressure. The extraction may be performed under pressure or normal pressure. Particularly preferable extraction conditions are an atmospheric pressure, an extraction temperature in the range of 75 to 90 ° C, and an extraction time in the range of 30 to 60 minutes.

[0020] Furthermore, it is possible to take a powdered hot water extract by spray drying or freeze drying, etc. In addition, tablets after adding excipients to this powdered powder Tablets and granules may be processed into tablets and granules.

[0021] The dosage of the therapeutic agent for malignant tumor of the present invention may vary depending on the disease state, the age of the patient, etc., but it is usually taken after extracting with hot water, preferably 10-30 g as the weight of dry matter per day. In this case, it is appropriate to extract this amount with 200-500g of hot water. When the hot water extract is spray-dried or freeze-dried and taken as an extract powder, granule, tablet, etc., the weight of the powdered product is suitably 3.0 to 6. Og.

[0022] The malignant tumor therapeutic agent of the present invention includes, for example, soups, various beverages (juice, alcohol, mineral water, etc.), confectionery (gum, candy, chocolate, snack, jelly, etc.), foods ( Soba, udon, ramen, etc.) and other general foods, health foods, nutritional supplements It can be set as the food / beverage products of this invention by mix | blending with foodstuffs (nutrition drink etc.). This makes it possible to take a malignant tumor therapeutic agent without resistance in daily life.

[0023] The concentration of the therapeutic agent for malignant tumor in the food and drink of the present invention can be appropriately changed depending on the type of food and drink. Normally, when a dry powder is mixed, the concentration per day When hot water extract is mixed as a spray-dried or freeze-dried extract powder, the daily intake is 2.2.0-12 when blended so that the intake is 10-50 g, preferably 20-30 g. . Og, preferably 3.0 to 6. Og. In addition, about the said density | concentration, it is an example and can be suitably changed according to various situations.

Example

[0024] Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.

[Example 1] Preparation of therapeutic agent for malignant tumor

Shiitake dry powder 3.0g, Maitake dry powder 3.0g, lemon balm dry powder 2.0g, mint dry powder 1. Og and stevia dry powder 1. Og and coarsely pulverized, with about 90 ° C hot water 300g The extract obtained by extracting for 40 minutes was named Example 1.

[Example 2] Preparation of therapeutic agent for malignant tumor

Shiitake mushroom powder 3.0g, Maitake mushroom powder 3.0g, Lemon balm mushroom powder 2.0g, Mint mushroom mushroom powder 1. Og and stevia mushroom mushroom powder 1.0g, Shimeji mushroom mushroom moulder powder 3.0m The dry extract obtained by mixing with Ochiya Building 2. Og was coarsely pulverized and extracted with 300 g of hot water at about 90 ° C for 40 minutes.

[Example 3] Preparation of therapeutic agent for malignant tumor

Shiitake dried powder 2.0g, maitake dried powder 2.0g, lemon balm dried powder 1.0g, mint dried powder 0.5g and stevia dried powder 0.5g mixed and coarsely crushed and heated with 300g hot water at about 90 ° C The extract obtained by extracting for 40 minutes was named Example 3.

[Example 4] Preparation of therapeutic agent for malignant tumor

Shiitake dry powder 2.0g, Maitake dry powder 2.0g, Lemon balm dry powder 1.0g, Mint dry powder 0.5g, Stevia dry powder 0.5g, Shimeji dry powder 2.0g, Celery seed dry powder 1. Og and Bichiya Building dry powder 1. Og is mixed and coarsely pulverized, then extracted with 300 g of hot water at about 90 ° C for 40 minutes. The obtained extract was designated as Example 4.

[0029] [Comparative Example 1] Preparation of shiitake mushroom single hot water extract

The extract obtained by roughly pulverizing 10 g of dried shiitake mushroom and extracting with 200 g of hot water at about 90 ° C. for 40 minutes was designated as Comparative Example 1.

[Comparative Example 2] Preparation of hot water extract of mint alone

The extract obtained by roughly pulverizing 10 g of dried mint and extracting with 200 g of hot water at about 90 ° C. for 40 minutes was used as Comparative Example 2.

[0031] [Test example]

[Test Example 1]

The clinical test results for confirming the therapeutic effect of the product of the present invention (Example 1) are as follows.

[Patient] SH o ⁷¹ 61 years old Spleen cancer

[Diagnosis] Spleen cancer

隱]

Treatment started 1. Five months ago: Diagnosis of spleen cancer was made with abdominal blunting as the first symptom, but at that time, it had already developed diabetes due to cancer infiltration throughout the spleen. He was admitted to the Sakai Cancer Center for scrutiny, and jaundice appeared. This is because the cancer invading the spleen reached the bile duct and blocked the biliary tract. The jaundice index in the blood increased and the blood alkaline phosphatase showed more than 1,500. Two metastases with a diameter of 4 cm or more have already been found (Figs. 1 and 2). At that time, the adaptability of the surgery was lost, an artificial stent was inserted into the biliary tract, symptomatic treatment was performed to ensure bile flow, and administration of anticancer drugs as prescribed was presented. In any case, doctors have announced that there is no life expectancy of more than 6 months. For diabetes, the oral diabetic drug Dalcobai was administered. Immediately after the administration of an anticancer drug by infusion (Gemzar = gemcitabine hydrochloride) and an internal anticancer drug T S-I, both were immediately discontinued due to severe side effects.

[0032] After the above-mentioned progress, he visited the (medicine) Chohakukai Ta Clinic. Fortunately, the inserted stent was successful, and at the time of the visit, it was still possible to eat food without jaundice, and fortunately, it was painful and painful with only the back pressure and dull pain. [0033] Based on the Eastern Medical Diagnosis, the therapeutic agent for malignant tumor of Example 1 was administered (the dosage of the therapeutic agent was 25 g as dry matter weight per day). I started by improving the quality of immunity. From our experience, “ki” in the Orient and “vital energy” in Europe have a very positive effect on the immune function of the human body. In this example, the power can be defeated in about 50 days, and it has progressed relatively smoothly since then. The changes in the tumor marker Dupan-2 below are likely to reflect the improvement (Figure 3). As the marker value decreased, the subjective symptoms were markedly improved. From the beginning of the treatment, there was no problem in daily life. After 6 months CT, the spleen that had been destroyed and expanded by the cancer invasion was reduced and the original figure was reduced. The metastasis to the large liver disappeared completely at all sites (Figs. 4 and 5). Currently returning to the workplace and considering the removal of the stent.

[0034] Thus, Eastern medical immunotherapy is characterized by the disappearance and improvement of the primary cancer site and the metastatic site to any part of the body at almost the same time. Note: This is fundamentally different from the therapeutic effect of only the treated area such as embolization or radiotherapy.

[0035] [Test Example 2]

The clinical test results for confirming the therapeutic effect of the product of the present invention (Example 2) are as follows.

[Patient] C.S. Early 61 years Uterine cancer

[Diagnosis] Uterine cancer

隱]

About 1 year before the start of treatment: I noticed abnormal bleeding and bad dew (falling goods), and visited a gynecologist. A well-known national hospital is introduced as close examination is necessary.

About 1 month after admission: As a result of a close examination, he was declared uterine cancer and underwent hysterectomy. At this time, there was partial invasion of the left ovary, and a total resection of the uterus and left ovary was performed. After the operation, all tumors were completely excised, and the cancer was infiltrated and metastasized locally. Therefore, treatment with anticancer drugs after surgery was unnecessary, and the patient was discharged immediately. After leaving the hospital, the patient had progressed at the first visit every three months. 6 months after the operation: I noticed something strange in the lower right abdomen and appealed to my doctor, but it was just enough to say, “Since all of the tumor was removed by the operation, it was just a concern.” Certainly, at that time, there were no abnormalities in ultrasonography or tumor markers.

10 months after surgery: The patient complained of abnormalities in the right lower abdomen over and over again, but this was not a problem. After applying for an abdominal CT scan, a fist-sized recurrent mass was found (Fig. 6). Because of the disappointment of the doctor's attitude at that time, the high rate of metastasis to others, the lack of other beneficial treatments including reoperation, and the doubt about anticancer drug treatment, I decided to seek a treatment other than Western modern medicine, and learned about treatment based on Eastern medicine. During that time, he decided to receive radiation therapy at the doctor's recommendation and treated for a specified period (Fig. 7).

Treatment start point (approximately 1 year after surgery): Administration of the malignant tumor therapeutic agent of Example 2 was started. The dose of the therapeutic agent was 25 g as dry matter weight per day. Life expectancy about 1-2 years, side effects due to radiation, and the ability to live mentally and physically unstable with strong general malaise and reduced vitality in life I regained my spirit and started eagerly working on treatment.

6 months after the start of treatment: The recurrence tumor in the pelvis that had existed before the treatment gradually decreased, and almost disappeared after 2 years. Instead, the intestinal tract is shown (Figure 8). Since then, it has now reached (six years after the start of treatment), but no signs of recurrence have been found either subjectively or objectively (images, blood tests). He is taking a therapeutic agent and is being followed up.

[Test Example 3]

The clinical test results for confirming the therapeutic effect of the product of the present invention (Example 4) are as follows.

[Patient] I. T. 0 ^ 52 years old Multiple myeloma

[Diagnosis] Multiple myeloma

隱]

10 months before the start of treatment: When hospitalized for left femoral fracture, he was told that the cause was multiple myeloma at this site. After the rest treatment, the osteosynthesis of the fracture site was successful. He continued to treat this malignant tumor. Continue hospitalization for 2 months Chemotherapy and radiation were combined. Chemotherapy was repeated for 4 days a month for 6 courses, and the radiation was aggravated with almost no improvement in power findings after a total of 20 irradiations (Figure 9). Subjective symptoms were repeated fever (hot feeling) and chills, and mosquitoes also showed significant edema throughout the body. The doctor recommended more powerful chemotherapy, but he felt life threatened by side effects and was forced to leave the hospital against the opinion of his doctor.

Treatment start point: From there, the treatment was changed to the treatment for administration of the malignant tumor therapeutic agent of Example 4. During the visit, he was accompanied by his family and visited with a wheelchair because of his general malaise and walking pain and wobble in his left leg. I decided to start treatment. The negative effects on the immune system due to the above-mentioned chemotherapy are the strength and strength of immunity. The immune function that can fight cancer in about 2 months when the treatment of the present invention is performed together with the normal diet. Could get. The dose of the therapeutic agent was 25 g as dry matter weight per day.

Three months after the start of treatment: Healing recovered rapidly from half a month after the start of treatment, and after two months, he relied on a cane on the stairs etc., but became able to visit alone. After that, it recovered smoothly, and after about a year, she visited the hospital without walking sticks. Bone scintigraphic findings were also clearly improved and reduced, and blood findings with abnormally high IgG levels were also normalized (Fig. 10). After about three and a half years, the X-ray findings have also improved (Fig. 11), and all subjective symptoms have disappeared, leading to a normal life. Unfortunately, all the patients who had been admitted to the previous hospital with the same disease name had died by then! /, U treatment started 4 years later: The treatment is ongoing for a more complete recovery .

[0037] The results of these three test examples clearly show that the product of the present invention has an effect of eliminating the tumor. Therefore, it was found that the product of the present invention is extremely effective for the treatment of malignant tumors. In the two-component administration group of the present invention (Comparative Examples 1 and 2), no clear efficacy was observed.

[0038] Next, examples of food and drink containing the malignant tumor therapeutic agent of the present invention are shown.

[Example 5]

Using the malignant tumor therapeutic agent obtained in Example 1, a candy containing 6.0% by weight of the malignant tumor therapeutic agent was prepared according to a conventional method.

[0040] [Example 6] Using the therapeutic agent for malignant tumor obtained in Example 2, tea containing 6.0% by weight of the therapeutic agent for malignant tumor was prepared according to a conventional method.

[0041] The food / beverage products containing the malignant tumor therapeutic agent of the above-mentioned example can be easily ingested in daily life and can effectively treat malignant tumors without side effects.

Brief Description of Drawings

[0042] [Fig. 1] CT image before treatment with this drug.

[Fig.2] CT image before treatment with this drug.

FIG. 3 is a graph showing changes in tumor marker Dupan-2.

[Fig. 4] CT image about 6 months after treatment with this drug.

[Fig.5] CT image about 6 months after treatment with this drug.

FIG. 6 is a CT image showing a recurrent tumor before treatment.

FIG. 7 is a CT image showing a recurrent tumor at the start of treatment.

FIG. 8 is a CT image showing disappearance of a cancer tumor after treatment with this drug.

FIG. 9 is a bone scintigraphic photograph of multiple myeloma before treatment with this drug.

FIG. 10 is a bone scintigraphic photograph of multiple myeloma one year after treatment with this drug.

[Fig. 11] A bone scintigraphic photograph of multiple myeloma about 3 and a half years after treatment with this drug.

Claims

The scope of the claims

[1] A malignant tumor therapeutic agent comprising a mixture obtained by mixing shiitake mushroom, maitake, lemon balm, mint and stevia as an active ingredient.

2. The malignant tumor therapeutic agent according to claim 1, further comprising an extract obtained by hot water extraction of the mixture.

3. The malignant tumor therapeutic agent according to claim 1 or 2, wherein the mixture is in a dry powder state.

[4] The malignant tumor therapeutic agent according to claim 3, wherein the weight ratio of the shiitake mushroom, maitake, lemon balm, mint and stevia is 3: 3: 2: 1: 1 in each dry state.

[5] The malignant tumor therapeutic agent according to any one of claims 1 to 4, wherein the malignant tumor therapeutic agent further includes at least one selected from the group consisting of shimeji, celery seed, and chirubiluka.

[6] The weight ratio of the shiitake mushroom, maitake, lemon balm, mint, stevia, shimeji, celery seed, and chia building is 3: 3: 2: 1: 1: 3: 2: 2 in each dry state. 5. The malignant tumor therapeutic agent according to 5.

[7] A food or drink containing the malignant tumor therapeutic agent according to any one of claims 1 to 6.